

1 **Title:**

2 **Surveillance of SARS-CoV-2 variants in Argentina: detection of Alpha, Gamma, Lambda,**
3 **Epsilon and Zeta in locally transmitted and imported cases**

4

5 ***Short communication***

6

7 **Authors:**

8 Torres Carolina^{1,2,*}, Mojsiejczuk Laura^{1,2,*}, Acuña Dolores^{2,3,*}, Alexay Sofía^{3,*}, Amadio Ariel^{2,4,§},
9 Aulicino Paula^{2,5,§}, Debat Humberto^{6,§}, Fernández Franco^{6,§}, Goya Stephanie^{3,§}, König Guido^{7,§},
10 Nabaes Jodar Mercedes^{2,3,§}, Pianciola Luis^{8,§}, Bengoa Sofía^{7,#}, Cacciahue Marco^{7,#}, Camussone
11 Cecilia^{4,#}, Dus Santos María José^{9,10,#}, Eberhardt María Florencia^{2,4,#}, Fernandez Ailen^{8,#},
12 Gismondi María Inés^{7,11,#}, Irazoqui Matías^{2,4,#}, Lusso Silvina^{3,#}, Marquez Nathalie^{6,#}, Muñoz
13 Marianne^{12,#}, Natale Mónica^{3,#}, Pisano Belén^{2,13,#}, Puebla Andrea^{12,#}, Re Viviana^{2,13,#}, Sosa
14 Ezequiel^{14,#}, Zaiat Jonathan^{14,#}, Zunino Sebastián^{11,15,#}, Do porto Darío^{14,#}, Acevedo María
15 Elina^{3,&}, Alvarez Lopez Cristina^{3,&}, Álvarez María Laura^{16,&}, Angeleri Patricia^{17,&}, Angelletti
16 Andrés^{18,19,&}, Arca Manuel^{20,&}, Barbas Gabriela^{21,&}, Bertone Ana^{37,&}, Bonnet Agustina^{20,&},
17 Bourlot Ignacio^{31,&}, Castello Alejandro^{22,&}, Castro Gonzalo^{23,&}, Ceriani Carolina^{24,&}, Cimino
18 Carlos^{25,&}, Cipelli Julián^{3,&}, Colmeiro María^{19,&}, Cordero Andrés^{18,&}, Cristina Carolina^{26,&}, Di Bella
19 Sofia^{19,&}, Ercole Regina^{19,&}, Espasandin Yesica^{16,&}, Espul Carlos^{27,&}, Falaschi Andrea^{27,&},
20 Fernandez Moll Facundo^{26,&}, Gatelli Andrea^{19,&}, Goñi Sandra^{22,&}, Jofré María Estela^{28,&}, Jaramillo
21 José^{15,&}, Labarta Natalia^{3,&}, Lacaze María Agustina^{29,&}, Larreche Rocio^{28,&}, Leiva Viviana^{28,&}, Levin
22 Gustavo^{31,&}, Luczak Erica^{32,&}, Mandile Marcelo^{22,&}, Massone Carla^{15,&}, Mazzeo Melina^{8,&},
23 Medina Carla^{3,&}, Monaco Belén^{15,&}, Montoto Luciana^{33,&}, Mugna Viviana^{34,&}, Musto
24 Alejandra^{32,&}, Ojeda Guillermo^{34,&}, Pintos Carolina^{8,&}, Pozzati Marcia^{35,&}, Rahhal Marilina^{36,&},
25 Rechimont Claudia^{37,&}, Remes Lenicov Federico^{38,&}, Rompató Gabriela^{34,&}, Seery Vanesa^{38,&}, Siri
26 Leticia^{31,&}, Spina Julieta^{39,&}, Streitenberger Cintia^{3,&}, Suárez Ariel^{40,&}, Suárez Jorgelina^{26,&},
27 Sujanski Paula^{17,&}, Talia Juan Manuel^{29,&}, Theaux Clara^{41,&}, Thomas Guillermo^{3,&}, Ticeira
28 Marina^{28,&}, Tittarelli Estefanía^{40,&}, Toro Rosana^{18,&}, Uez Osvaldo^{25,&}, Zaffanella María Belén^{39,&},
29 Ziehm Cecilia^{8,&}, Zubieta Martin^{36,&}, on behalf of PAIS Consortium[∞], Mistchenko Alicia^{3,42},
30 Valinotto Laura^{2,3}, Viegas Mariana^{2,3}, @

31 *, §, #, & equally contributing authors

32 @ corresponding author

33 [∞]<http://pais.qb.fcen.uba.ar/>

- 34 1. Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de
35 Investigaciones en Bacteriología y Virología Molecular (IBaViM), Buenos Aires, Argentina.
- 36 2. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires,
37 Argentina.
- 38 3. Laboratorio de Virología, Hospital de Niños Dr. Ricardo Gutiérrez, CABA, Argentina.
- 39 4. Instituto de Investigación de la Cadena Láctea (IDICAL) INTA-CONICET. Ruta 34 km 227,
40 Rafaela (2300), Santa Fe, Argentina.
- 41 5. Laboratorio de Biología Celular y Retrovirus. Hospital de Pediatría "Prof. Juan P. Garrahan",
42 CABA, Argentina.
- 43 6. Instituto de Patología Vegetal – Centro de Investigaciones Agropecuarias – Instituto
44 Nacional de Tecnología Agropecuaria (IPAVE-CIAP-INTA), Camino 60 Cuadras Km 5,5
45 (X5020ICA), Córdoba, Argentina.
- 46 7. Instituto de Biotecnología/Instituto de Agrobiotecnología y Biología Molecular (INTA-
47 CONICET), Hurlingham, Buenos Aires, Argentina.
- 48 8. Laboratorio Central ciudad de Neuquén, Ministerio de Salud, Neuquén, Argentina.
- 49 9. Instituto de Virología e Innovaciones Tecnológicas (INTA-CONICET), Hurlingham, Buenos
50 Aires, Argentina.
- 51 10. Laboratorio de Diagnóstico-UNIDAD COVID- Universidad Nacional de Hurlingham,
52 Hurlingham, Buenos Aires, Argentina.
- 53 11. Universidad Nacional de Luján, Departamento de Ciencias Básicas, Argentina. Ruta
54 Nacional 5 y Av. Constitución, 6700, Luján.
- 55 12. Unidad de Genómica del Instituto de Biotecnología/Instituto de Agrobiotecnología y
56 biología Molecular (INTA-CONICET), Hurlingham, Buenos Aires, Argentina.
- 57 13. Instituto de Virología "Dr. J. M. Vanella", Facultad de Ciencias Médicas, Universidad
58 Nacional de Córdoba.
- 59 14. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales (IQUIBICEN),
60 CONICET, Ciudad de Buenos Aires, Argentina.
- 61 15. Laboratorio de Virología Molecular, Hospital Blas L. Dubarry de Mercedes, provincia de
62 Buenos Aires, Argentina.
- 63 16. Laboratorio del Hospital Zonal Dr. Ramón Carrillo, San Carlos De Bariloche, provincia de Río
64 Negro, Argentina
- 65 17. Comité Operativo de Emergencia COVID, Ministerio de Salud de la Ciudad Autónoma de
66 Buenos Aires, Argentina.
- 67 18. Laboratorio de salud pública, Facultad de Ciencias Exactas, UNLP, La Plata, Provincia de
68 Buenos Aires, Argentina.

- 69 19. Laboratorio de Virología, HIEAyC "San Juan de Dios", La Plata, provincia de Buenos Aires,
70 Argentina.
- 71 20. Laboratorio de Virología del Hospital JJ Urquiza, Concepción del Uruguay, provincia de
72 Entre Ríos, Argentina
- 73 21. Secretaria de Prevención y Promoción, Ministerio de Salud de la provincia de Córdoba,
74 Argentina.
- 75 22. Plataforma de Servicios Biotecnológicos; UTTIPP/PSB, Bernal, provincia de Buenos Aires,
76 Argentina.
- 77 23. Laboratorio Central de la Provincia de Córdoba, Ministerio de Salud la provincia de
78 Córdoba, Argentina.
- 79 24. Laboratorio de Virología de la Facultad de Veterinaria de la Universidad Nacional del
80 Centro de la provincia de Buenos Aires (UNCPBA), Tandil, provincia de Buenos Aires,
81 Argentina.
- 82 25. Instituto Nacional de Epidemiología "Dr. Jara" (Mar del Plata, provincia de Buenos Aires,
83 Argentina.
- 84 26. Centro de Investigaciones Básicas y Aplicadas, UNNOBA, Junín, provincia de Buenos Aires,
85 Argentina.
- 86 27. Dirección de epidemiología y Red de Laboratorios del Ministerio de Salud de la provincia
87 de Mendoza, Argentina.
- 88 28. Laboratorio de Biología Molecular Bolívar, LABBO, Bolívar, provincia de Buenos Aires,
89 Argentina.
- 90 29. Programa Laboratorio de Salud Pública "Dr Dalmiro Pérez Laborda", Ministerio de Salud de
91 la provincia de San Luis, Argentina.
- 92 30. Laboratorio De Salud Pública, Ciudad de Mendoza, provincia de Mendoza, Argentina.
- 93 31. Laboratorio de biología molecular del Hospital Centenario, Gualeguaychú, provincia de
94 Entre Ríos, Argentina.
- 95 32. Laboratorio del Hospital Interzonal General de Agudos "Evita", Lanús, provincia de Buenos
96 Aires, Argentina.
- 97 33. Laboratorio de Biología Molecular Hospital Pedro de Elizalde, Ciudad Autónoma de Buenos
98 Aires, Argentina.
- 99 34. Laboratorio Central, ciudad de Santa Fe, provincia de Santa Fe. Argentina.
- 100 35. Laboratorio de Biología Molecular, Hospital Cosme Argerich, Ciudad Autónoma de Buenos
101 Aires, Argentina.
- 102 36. Laboratorio de Hospital El Cruce Dr. Néstor C. Kirchner, CEMET, Florencio Varela, provincia
103 de Buenos Aires, Argentina.

- 104 37. Laboratorio de la Dirección de Epidemiología, Santa Rosa, provincia de La Pampa,
105 Argentina.
- 106 38. Instituto de Investigaciones Biomédicas en Retrovirus y Sida, CONICET-UBA, Ciudad
107 Autónoma de Buenos Aires, Argentina.
- 108 39. Laboratorio de Biología Molecular. Hospital Dr. Héctor Cura, Olavarría, provincia de
109 Buenos Aires, Argentina.
- 110 40. Departamento de Biología y genética molecular; IACA Laboratorios, Bahía Blanca, provincia
111 de Buenos Aires, Argentina.
- 112 41. Laboratorio de Biología molecular del Hospital General de Agudos Dr. Carlos G. Durand,
113 Ciudad Autónoma de Buenos Aires, Argentina.
- 114 42. Comisión de Investigaciones Científicas de la provincia de Buenos Aires, Argentina.
- 115

116 **Abstract**

117 Molecular surveillance of SARS-CoV-2 variants was performed on a total of 2,406 samples from
118 the capital city and nine provinces of Argentina, during 30 epidemiological weeks (EW) that
119 covered the end of the first wave and the beginning of the ongoing second wave of the COVID-
120 19 pandemic in the country (EW 44/2020 to EW 20/2021). The surveillance strategy was
121 mainly based on Sanger sequencing of a Spike coding region that allows the simultaneous
122 identification of signature mutations associated with worldwide circulating variants. In
123 addition, whole SARS-CoV-2 genome sequences were obtained from 456 samples. The main
124 variants found were Gamma, Lambda and Alpha, and to a lesser extent, Zeta and Epsilon.
125 Whereas Gamma dominated in different regions of the country, both Gamma and Lambda
126 prevailed in the most populated area, the metropolitan region of Buenos Aires (MABA),
127 although showing a heterogeneous distribution along this region. This cost-effective
128 surveillance protocol allowed for a rapid response in a limited access to resources scenario,
129 added information on the expansion of the Lambda variant in South America and contributed
130 to the implementation of public health measures to control the disease spread in
131 Argentina.

132

133 **KEYWORDS:** SARS-CoV-2; variants; South America; Argentina; surveillance; Spike sequence

134 **Main text**

135 The emergence of SARS-CoV-2 variants with concerning characteristics to public health has
136 attracted the attention of the scientific community and governments both regionally and
137 globally since the end of 2020. The most relevant variants described so far include: Alpha
138 (lineage B.1.1.7), first detected in the United Kingdom; Beta (lineage B.1.351), initially detected
139 in South Africa; Gamma (lineage P.1, derived from lineage B.1.1.28), initially detected in
140 Manaus, Brazil, and Japan; Delta (lineage B.1.627.2), initially detected in India; Epsilon
141 (lineages B.1.427 and B.1.429), initially detected in California, United States; Zeta (lineage P.2,
142 derived from lineage B.1.1.28), first detected in Rio de Janeiro, Brazil; and Lambda (lineage
143 C.37, derived from B.1.1.1), initially detected in Peru (1). Four of these variants (Alpha to Delta)
144 have been defined as variants of concern (VOC) given their increased transmissibility and other
145 characteristics (1). They have also been associated with an increased risk of hospitalization
146 (2,3) and, in the case of Beta, Gamma and Delta, with a moderate to substantial reduction in
147 neutralizing activity of monoclonal antibodies, convalescent and vaccine sera (4–6).

148 Gamma and Lambda are particularly relevant for Argentinean public health due to their
149 significant presence in the South American region. Importantly, some of these variants share
150 distinct mutations in the Spike protein -several of them in the receptor binding domain (RBD)
151 region- that potentially affect transmissibility, pathogenesis and/or response to vaccination
152 and immune-based therapies.

153 PAIS is the inter-institutional federal consortium of SARS-CoV-2 genomics in Argentina. It was
154 created by the Ministry of Science and Technology to monitor SARS-CoV-2 diversity and
155 evolution in the country, including surveillance of SARS-CoV-2 variants of public health interest
156 (<http://pais.qb.fcen.uba.ar/>).

157 Between October 26th, 2020 and May 22nd, 2021 (epidemiological week (EW)44/2020 to
158 EW20/2021), molecular surveillance was performed on a total of 2,406 samples from the
159 capital city and nine provinces of the country, including the four most populated districts
160 (Figure 1 and Table 1). This period covers the end of the first wave and the beginning of the
161 ongoing second and largest wave of the COVID-19 pandemic in Argentina (Figure 2). During
162 that period, the frontiers were mostly open for Argentinean residents, but the foreigners had
163 severe restrictions to enter the country as tourists.

164 For this work, samples analyzed included a randomly selected 2.5-10% fraction of the total
165 positive cases weekly detected in different health care centers. Regular sampling from four
166 sentinel laboratories located in the metropolitan area of Buenos Aires (MABA) was performed
167 along with sporadic sampling from other locations to sum up a total of 1,950 sequences.

168 Surveillance strategy was based on Sanger sequencing of a 970bp region of Spike spanning
169 amino acids 428 to 750 (Figure 3) (7). This region allows the identification of signature
170 mutations associated with variants Alpha, Beta, Gamma, Lambda and Delta. Additionally,
171 complete SARS-CoV-2 genome sequences were obtained from 456 samples using the Quick
172 protocol (8) with Oxford Nanopore or Illumina platforms and combined with partial sequences
173 to perform the analysis of 2,406 sequences (Table 1).

174 In this work we show genomic evidence of SARS-CoV-2 local transmission of variants Alpha,
175 Gamma, Lambda, Epsilon and Zeta in Argentina, as well as the detection of mutations
176 Spike_L452R and Spike_E484K in different geographic regions of the country.

177 **Alpha** was identified in 220 cases. This variant was detected in the city of Buenos Aires (CABA)
178 and in the provinces of Buenos Aires, Córdoba, Entre Ríos, Santa Fe, San Luis, La Pampa and
179 Neuquén. Its frequency in most of the MABA region (CABA plus Great Buenos Aires (GBA))
180 reached 19.8% (95% CI = 13.3-28.5) in EW 15/2021 (April 11th to 17th) but decreased to 10.9%
181 (95% CI = 5.1-21.2) in EW 20/2021 (May 16th to 22nd) (Tables 1-2 and Figure 2). The
182 phylogenetic analysis of whole genome sequences (including 127 from Argentina, 43 from this
183 work) showed at least 35 independent introductions to the country, being the most related
184 sequences from the USA, Central America, Europe, and the Middle East. Besides, five highly
185 supported groups with at least three Argentinean sequences were observed (Figure 4). The
186 largest group included 53 sequences from the CABA and nine provinces, from north to south of
187 the country, suggesting a widespread local transmission and diversification.

188 **Gamma** was identified in a total of 499 cases. This variant was detected in the CABA and in the
189 provinces of Buenos Aires, Córdoba, Santa Fe, Entre Ríos, La Pampa, San Luis, Mendoza and
190 Neuquén. Its frequency in the CABA and GBA remained stable at values over 30% since EW
191 16/2021, reaching 39.1% (95% CI = 28.0-51.3) in the EW 20/2021. The phylogenetic analysis of
192 complete genome sequences (including 238 from Argentina, 50 from this work) showed at
193 least 50 introductions to Argentina, with the most related sequences from Brazil and the USA.
194 Besides, 18 supported groups with at least three Argentinean sequences were observed
195 (Figure 5). The largest one included 72 sequences from the CABA and 14 provinces, from north
196 to south of the country, also suggesting widespread local transmission and diversification
197 (Figure 5.d). Eight sequences from Argentina were located in a separate clade within P.1
198 (previously named as P.1-like-II, (9)). This clade was formed by sequences from South America
199 only (Brazil, Chile and Argentina) (Figure 5), showing a regional diversification process.

200 **Lambda** variant showed a continuous increase since EW 7/2021 in the CABA and the GBA,
201 reaching frequencies of 48.4% (95% CI = 36.6-60.4) in the EW 20/2021. Noteworthy, this

202 variant appears to have replaced Alpha variant in the most populated region of the country
203 (Table 2), given that since EW 15/2021, the proportion of cases associated with Alpha
204 decreased while those associated with Lambda increased. These data have contributed to its
205 recent declaration as a global VOI by the WHO (1). The transmission capacity, clinical behavior,
206 and impact on vaccine effectiveness of this VOI will need further studies. However, preliminary
207 studies have shown that the neutralization capacity of convalescent sera from the first wave
208 viruses in Argentina and sera from individuals vaccinated with Sputnik V was not compromised
209 (BBEI, 2021). On the other hand, increased infectivity and resistance to neutralizing antibodies
210 produced by individuals immunized with CoronaVac (SinoVac) and mRNA-1273 (Moderna)
211 vaccines was observed (10,11).

212 In addition, a probable case of coinfection of Alpha and Gamma was identified in a sample
213 from the city of La Plata, and also two other cases of possible coinfection between Alpha and
214 Lambda in the CABA. These cases will be further analyzed.

215 Importantly, the proportion of cases associated with Alpha and Gamma among individuals with
216 no travel history or contact with travelers in CABA and GBA increased from less than 3% in the
217 EW 7/2021-EW 9/2021 to 50.0% (for joint frequencies) in the EW 20/2021, and adding
218 Lambda, they surpassed 98% of the total samples at that EW (Table 2).

219 However, the distribution of variants of epidemiological interest between EW 9/2021 and EW
220 20/2021 was heterogeneous within the MABA (Figure 6). While North GBA presented a
221 predominance of Gamma (16/39 cases, 41.0%) and 9/39 cases of Lambda (23.1%), west GBA
222 presented a more even distribution of variants, with Lambda in 58/176 cases (33.0%), Gamma
223 in 49/176 cases (27.8%), and Alpha in 34/176 cases (19.3%). Similarly, the CABA presented
224 Lambda in 150/508 cases (29.5%), Gamma in 110/508 cases (21.7%), and Alpha in 67/508
225 cases (13.2%). On the contrary, south GBA presented a predominance of Lambda (127/253
226 cases, 50.2%), followed by Gamma in 47/253 cases (18.6%) and Alpha in 10/253 cases (4.0%).
227 Lastly, Great La Plata (GLP) showed a strong predominance of Gamma, counting 43/61 (70.5%).

228 The analysis of the sporadic sampling from several places of the country also revealed a
229 heterogeneous distribution of variants, showing a high proportion of cases associated with
230 different variants and mutations of interest, especially with Gamma in most of the provinces
231 studied (Table 1).

232 Therefore, the major lineages that circulated on the first wave at the beginning of the studied
233 period were almost completely replaced by worldwide and regional emergent variants in a
234 term of few weeks (Figure 2 and Figure 6), as was previously observed in other countries.

235 It is worth noting that data about the dynamics of the co-circulation of these highly
236 transmissible variants are limited, given that in most countries only one of them became
237 rapidly dominant and the introduction of a second VOC occurred after the first was already
238 established. However, according to our data from several regions of Argentina, VOCs and VOIs
239 presented similar frequencies in the population at the time of writing this report, which could
240 allow proper comparative analyses of their dynamics, severity, and impact on vaccine
241 effectiveness.

242 Mutations at aa positions 484 and 452 of Spike protein have been associated with possible
243 immune escape and modified affinity to the human receptor and may occur in various newly
244 emerging lineages worldwide (11–14). Both positions are located within the RBM (receptor
245 binding motif). On one hand, the E484K mutation, constitutively present in Beta, Gamma, Zeta,
246 Eta and Iota variants, was associated with resistance to neutralization by monoclonal
247 antibodies, convalescent and vaccinated sera (4,12,15–17). On the other hand, mutations at
248 position 452 of the Spike protein, were associated with decreased neutralization by
249 monoclonal antibodies, convalescent and some vaccine sera (12,13). Another important
250 mutation in Spike is P681R, associated with an enhanced viral fusion (18), which was not
251 detected in this work.

252 The E484K mutation - not associated with Beta or Gamma signatures- was found in 138 cases.
253 Most of the samples come from the CABA and the GBA regions from individuals without travel
254 history, suggesting local circulation, at least, since the last week of December 2020, when it
255 was first detected by our surveillance program. Nevertheless, a reduction in its frequency was
256 observed since EW 12/2021 in the CABA and the GBA, being almost completely replaced by
257 VOCs and VOIs of more recent emergence, such as Lambda (Table 2). So far, 53 of 138 cases
258 analyzed by full-length sequencing have been identified as belonging to the Zeta variant
259 through the analysis of the complete genome.

260 For the L452R mutation, a similar replacement has been observed, being occasionally detected
261 in the CABA and the GBA between the EW 1/2021 and the EW 13/2021, but not thereafter.
262 The complete genome analysis of 21 cases allowed to identify the Epsilon variant in 18 cases:
263 one from lineage B.1.429 and 17 from lineage B.1.427. None of the L452R cases detected so
264 far were associated with Delta or Kappa variants.

265 In conclusion, the surveillance strategy implemented over 30 epidemiological weeks in
266 Argentina, based on Spike and complete genome sequencing, allowed to describe the
267 introduction, establishment, and evolution of SARS-CoV-2 variants of interest and concern in
268 the second wave of the COVID-19 pandemic in South America. The main variants found were

269 Gamma, Lambda and Alpha, in that order, with lower detection of Zeta and Epsilon. This
270 implementation allowed a rapid response in a limited resource access scenario and
271 contributed to the implementation of public health measures to control disease spread.
272

273 **Table 1.** Cumulative cases analyzed in this work from different regions of Argentina.

274

Region	Area or city	Period	Alpha	Gamma	Lambda	E484K	L452R	Non VOC/VOI	TOTAL
CABA (part of MABA)		2020-10-26 to 2021-05-22	81	121	160	67	10	427	866
GBA (part of MABA)	North	2020-12-21 to 2021-05-21	5	16	10	4	0	32	67
	West	2020-11-28 to 2021-05-22	35	50	59	17	3	108	272
	South	2020-10-26 to 2021-05-22	10	47	138	27	5	163	390
GLP (part of MABA)		2020-11-27 to 2021-04-24	1	43	13	1	2	31	91
MABA	unknown	2021-02-14 to 2021-05-21	3	2	7	0	0	7	19
PBA (outside MABA)	Several cities	2020-11-27 to 2021-05-21	42	44	48	17	3	82	236
Córdoba	Several cities	2020-11-03 to 2021-05-21	18	23	16	4	11	83	155
Santa Fe	Several cities	2020-12-11 to 2021-05-22	9	68	6	0	3	59	145
Entre Ríos	Several cities	2021-05-11 to 2021-05-14	11	20	3	0	0	3	37
La Pampa	Santa Rosa	2021-05-16 to 2021-05-17	1	11	1	0	0	0	13
San Luis	Several cities	2021-04-02 to 2021-04-17	3	14	3	0	0	10	30
Mendoza	General Alvear	2021-03-22 to 2021-04-08	0	15	0	0	0	0	15
Neuquén	Several cities	2021-01-03 to 2021-05-15	1	25	1	0	2	33	62
Río Negro	Bariloche	2021-12-21 to 2021-03-09	0	0	0	1	0	7	8
TOTAL		2020-10-26 to 2021-05-22	220	499	465	138	39	1045	2406

275 Note: The total in CABA (n = 866) does not include two co-infections (Alpha/Lambda) and the total in GLP (n = 91) does not include one co-infection
 276 (Alpha/Gamma).

277 CABA: Buenos Aires city. GBA: Great Buenos Aires. GLP: Great La Plata. MABA: Metropolitan area of Buenos Aires. PBA: Buenos Aires province.

278

279 **Table 2.** Frequency of Alpha and Gamma, and mutations E484K and L452R by epidemiological week (EW) 2020-2021 in the Metropolitan Area of Buenos Aires (MABA).

EW	Alpha		Gamma		Lambda		Mutation E484K ³		Mutation L452R ⁴		Non VOC/VOI		Total of sequences ¹
	Frequency (%)	95%CI ²	Frequency (%)	95%CI ²	Frequency (%)	95%CI ²	Frequency (%)	95%CI ²	Frequency (%)	95%CI ²	Frequency (%)	95%CI ²	
44-51	0,0	-	0,0	-	0,0	-	5,4	2.0-12.3	0,0	-	94,6	87.7-98.0	93
52	0,0	-	0,0	-	0,0	-	1,5	<0.01-8.6	0,0	-	98,5	91.4-100	68
53	0,0	-	0,0	-	0,0	-	1,5	<0.01-8.9	0,0	-	98,5	91.1-100	66
1	0,0	-	0,0	-	0,0	-	1,5	<0.01-8.8	1,5	<0.01-8.8	97,0	89.1-99.8	67
2	0,0	-	0,0	-	0,0	-	8,7	2.9-20.9	0,0	-	91,3	79.1-97.1	46
3	0,0	-	0,0	-	3,0	<0.01-16.7	15,2	6.2-31.4	3,0	<0.01-16.7	78,8	62.0-89.6	33
4	0,0	-	0,0	-	0,0	-	14,3	5.8-29.9	0,0	-	85,7	70.1-94.2	35
5	4,4	<0.01-22.7	0,0	-	0,0	-	26,1	12.3-46.8	0,0	-	69,6	48.9-84.6	23
6	0,0	-	0,0	-	0,0	-	19,4	9.5-35.3	2,8	<0.01-15.4	77,8	61.7-88.5	36
7	1,9	<0.01-10.7	0,0	-	9,3	3.6-20.3	18,5	10.2-31.0	1,9	<0.01-10.7	68,5	55.2-79.4	54
8	1,6	<0.01-9.1	0,0	-	12,5	6.2-23.0	14,1	7.4-24.8	0,0	-	71,9	59.8-81.5	64
9	6,7	3.1-13.5	1,0	<0.01-5.8	16,4	10.4-24.7	10,6	5.9-18.1	3,9	1.2-9.8	61,5	51.9-70.3	104
10	7,0	3.2-14.0	2,0	0.1-7.4	18,0	11.6-26.8	14,0	8.4-22.3	4,0	1.2-10.2	55,0	45.2-64.4	100
11	16,7	9.6-27.1	5,6	1.8-13.8	18,1	10.7-28.6	20,8	12.9-31.7	2,8	0.2-10.2	36,1	26.0-47.7	72
12	13,7	8.2-21.9	11,8	6.7-19.6	33,3	24.9-43.0	9,8	5.2-17.3	2,9	0.6-8.7	28,4	20.6-37.9	102
13	18,5	11.4-28.5	16,1	9.5-25.7	40,7	30.7-51.6	3,7	0.8-10.8	1,2	<0.01-7.3	19,8	12.4-29.8	81
14	7,8	3.8-14.9	34,3	25.8-44.0	47,1	37.7-56.7	0,0	-	0,0	-	10,8	6.0-18.4	102
15	19,8	13.3-28.5	32,1	23.9-41.5	38,7	30.0-48.2	2,8	0.6-8.4	0,0	37.0-65.0	6,6	3.0-13.2	106
16	12,0	6.2-21.5	40,0	29.7-51.3	38,7	28.4-50.0	2,7	0.2-9.8	0,0	-	6,7	2.5-15.0	75
17	11,8	6.3-20.5	41,2	31.3-51.8	41,2	31.3-51.8	2,4	0.1-8.7	0,0	-	3,5	0.8-10.3	85
18	4,7	0.4-16.3	32,6	20.4-47.6	58,1	43.3-71.6	0,0	-	0,0	-	4,7	0.4-16.3	43
19	9,5	3.2-22.6	40,5	27.0-55.5	47,6	33.4-62.3	2,4	<0.01-13.4	0,0	-	0,0	-	42
20	10,9	5.1-21.2	39,1	28.0-51.3	48,4	36.6-60.4	0,0	-	0,0	-	1,6	<0.01-9.1	64

280 ¹ Only the cases from the MABA region that did not present a history of travel or close contact with travelers are included; in cases with a known epidemiological link between
281 samples, only one was included in this table.

282 ² The adjusted confidence interval of the frequency was estimated by the modified Wald method (19).


283 ³ Includes detections of the E484K mutation that do not belong to sequences with the characteristic combination of mutations of Gamma or Beta variants.

284 ⁴ Includes detections of the L452R mutation that do not belong to sequences with the characteristic combination of mutations of Delta or Kappa variants.

285


286 **Figures**

287



289 **Figure 1.** Location of cases analyzed in this work and pie charts representing the frequency of
290 each variant detected in every region between EW44/2020 to EW20/2021. 1. Buenos Aires
291 city, 2. Great Buenos Aires (North, West, South), 3. Province of Buenos Aires, 4. Province of
292 Córdoba, 5. Province of Santa Fe, 6. Province of Entre Ríos, 7. Province of La Pampa, 8.
293 Province of San Luis, 9. Province of Mendoza, 10. Province of Neuquén, 11. Province of Río
294 Negro.

295




296

297 **Figure 2.** Number of reported cases by epidemiological week 2020-2021 since the beginning of
298 the molecular surveillance of SARS-CoV-2 variants. Only cases that did not present a history of
299 travel or close contact with travelers are included. Dotted line (mapped to the left y axis)
300 indicates the average number of confirmed COVID-19 cases per week in the Metropolitan Area
301 of Buenos Aires (MABA).

302

303




304

305 **Figure 3.** Representation of the amino acid changes in the S gene of SARS-CoV-2 variants of
 306 epidemiological interest. Changes indicated in red correspond to those with the greatest
 307 potential impact on viral biology or neutralization by antibodies. The location of CDC fragment
 308 29 (codons 428 to 750) used for active surveillance of variants is indicated.


309

310




311

312 **Figure 4** Phylogenetic tree of SARS-CoV-2 whole genome sequences of Alpha (lineage B.1.1.7). Dataset included reference sequences from Argentina, their best five
313 BLAST hits sequences (against GISAID database on June 2nd 2021), reference sequences of B.1.1.7 lineage, and B.1.1.1 sequences as outgroup. Only the largest
314 group with Argentinean sequences is shown. Phylogenetic analysis was performed using IQ-TREE v. 2.1.2 COVID-edition (20). The SH-like approximate
315 likelihood ratio test (1000 replicates) (21) and Ultrafast bootstrap Approximation (1000 replicates) (22) were used as methods to evaluate the reliability of the
316 groups obtained. The SH-like / UFB values for the relevant groups are indicated for some groups. We gratefully acknowledged the authors from the originating
317 laboratories responsible for obtaining the specimens and the submitting laboratories where genetic sequence data were generated and shared via the GISAID
318 Initiative, on which part of this research is based (Table S1).



319
 320 **Figure 5.** Phylogenetic tree of SARS-CoV-2 whole genome sequences of Gamma (lineage P.1). Dataset included sequences from Argentina, their best five BLAST
 321 hits sequences (against GISAID database on June 2nd 2021), reference sequences of P.1 lineage, and B.1.1.28 sequences as outgroup. Only selected groups with
 322 Argentinean sequences are shown. Phylogenetic analysis was performed as previously described in Figure 5. *P.1-like-I and **P.1-like-II described by Gräf et al
 323 (9). We gratefully acknowledge the authors from the originating laboratories responsible for obtaining the specimens and the submitting laboratories where
 324 genetic sequence data were generated and shared via the GISAID Initiative, on which part of this research is based (Table S2).



325

326 **Figure 6.** Cumulative number of SARS-CoV-2 variants and sequences with or without mutations
 327 of interest in the Metropolitan area of Buenos Aires (CABA, GBA and Great La Plata (GLP)). The
 328 cases were analyzed in two periods: until EW 8/2021 and from EW 9/2021 to EW 20/2021,
 329 according to the moment of change in the trend of the frequencies of the variants or
 330 mutations in each region. Only cases that did not present a history of travel or close contact
 331 with travelers are included; in cases sharing an epidemiological link, only one was considered
 332 as representative. The bars show the number of samples corresponding to variants, mutations
 333 or non-VOC/non-mutations of interest.

334

335

336 References

- 337 1. WHO. Weekly epidemiological update on COVID-19 - 15 June 2021 [Internet]. 2021.
 338 Available from: [https://www.who.int/publications/m/item/weekly-epidemiological-update-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---15-june-2021)
 339 [on-covid-19---15-june-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---15-june-2021)
- 340 2. Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M, et al. Characteristics of SARS-CoV-
 341 2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks
 342 38/2020 to 10/2021. *Eurosurveillance* [Internet]. 2021;26(16). Available from:
 343 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348>
- 344 3. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland:
 345 demographics, risk of hospital admission, and vaccine effectiveness. *Lancet* [Internet].
 346 2021;397(10293):2461–2. Available from: [http://dx.doi.org/10.1016/S0140-6736\(21\)01358-](http://dx.doi.org/10.1016/S0140-6736(21)01358-1)
 347 1
- 348 4. Garcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple
 349 SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. *Cell*
 350 [Internet]. 2021 Apr 29;184(9):2372-2383.e9. Available from:

- 351 <https://doi.org/10.1016/j.cell.2021.03.013>
- 352 5. Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, et al. Increased Resistance of SARS-
353 CoV-2 Variant P.1 to Antibody Neutralization. *bioRxiv* [Internet]. 2021 Jan
354 1;2021.03.01.433466. Available from:
355 <http://biorxiv.org/content/early/2021/04/09/2021.03.01.433466.abstract>
- 356 6. Biobanco de Enfermedades Infecciosas. Seroneutralización de variantes SARS-CoV-2
357 Gamma (P.1, Manaus), Alpha (B.1.1.7, Reino Unido) y Lambda (C.37, Andina) en
358 individuos vacunados con Sputnik V e individuos recuperados de la infección por SARS-CoV-
359 2 [Internet]. 2021. Available from:
360 http://pais.qb.fcen.uba.ar/files/reportes/informe_seroneutralizacion_C37_P1.pdf
- 361 7. Paden C, Tao Y, Queen K, Zhang J, Li Y, Uehara A, et al. Rapid, Sensitive, Full-Genome
362 Sequencing of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis J*
363 [Internet]. 2020;26(10):2401. Available from: [https://wwwnc.cdc.gov/eid/article/26/10/20-](https://wwwnc.cdc.gov/eid/article/26/10/20-1800_article)
364 [1800_article](https://wwwnc.cdc.gov/eid/article/26/10/20-1800_article)
- 365 8. Quick J. nCoV-2019 sequencing protocol v3 (LoCost) V.3 [Internet]. 2020. Available from:
366 <https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye>
- 367 9. Gräf T, Bello G, Martins Venas TM, Cavalcante Pereira E, Dias Paixão AC, Reis Appolinario L,
368 et al. Identification of SARS-CoV-2 P.1-related lineages in Brazil provides new insights about
369 the mechanisms of emergence of Variants of Concern [Internet]. Available from:
370 [https://virological.org/t/identification-of-sars-cov-2-p-1-related-lineages-in-brazil-provides-](https://virological.org/t/identification-of-sars-cov-2-p-1-related-lineages-in-brazil-provides-new-insights-about-the-mechanisms-of-emergence-of-variants-of-concern/694)
371 [new-insights-about-the-mechanisms-of-emergence-of-variants-of-concern/694](https://virological.org/t/identification-of-sars-cov-2-p-1-related-lineages-in-brazil-provides-new-insights-about-the-mechanisms-of-emergence-of-variants-of-concern/694)
- 372 10. Acevedo ML, Alonso-Palomares L, Bustamante A, Gaggero A, Paredes F, Cortés CP, et
373 al. Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda.
374 *medRxiv* [Internet]. 2021 Jan 1;2021.06.28.21259673. Available from:
375 <http://medrxiv.org/content/early/2021/07/01/2021.06.28.21259673.abstract>
- 376 11. Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR. SARS-CoV-2
377 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies
378 and Convalescent Serum. *bioRxiv* [Internet]. 2021 Jan 1;2021.07.02.450959. Available from:
379 <http://biorxiv.org/content/early/2021/07/03/2021.07.02.450959.abstract>
- 380 12. Liu Z, VanBlargan LA, Bloyet L-M, Rothlauf PW, Chen RE, Stumpf S, et al. Identification
381 of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody
382 neutralization. *Cell Host Microbe*. 2021 Mar;29(3):477-488.e4.
- 383 13. Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, et al. Deep

- 384 Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on
385 Folding and ACE2 Binding. *Cell* [Internet]. 2020;182(5):1295-1310.e20. Available from:
386 <https://www.sciencedirect.com/science/article/pii/S0092867420310035>
- 387 14. Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, et al.
388 Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in
389 California carrying a L452R spike protein mutation. *medRxiv* [Internet]. 2021 Jan
390 1;2021.03.07.21252647. Available from:
391 <http://medrxiv.org/content/early/2021/03/09/2021.03.07.21252647.abstract>
- 392 15. Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JCC, et al. Escape from
393 neutralizing antibodies by SARS-CoV-2 spike protein variants. Marsh M, van der Meer JWM,
394 Montefiore D, editors. *Elife* [Internet]. 2020;9:e61312. Available from:
395 <https://doi.org/10.7554/eLife.61312>
- 396 16. Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, et al. Complete Mapping
397 of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody
398 Recognition. *Cell Host Microbe* [Internet]. 2021 Jan 13;29(1):44-57.e9. Available from:
399 <https://doi.org/10.1016/j.chom.2020.11.007>
- 400 17. Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to
401 SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.
402 *Science* (80-) [Internet]. 2020 Aug 21;369(6506):1014 LP – 1018. Available from:
403 <http://science.sciencemag.org/content/369/6506/1014.abstract>
- 404 18. Saito A, Nasser H, Uriu K, Kosugi Y, Irie T, Shirakawa K, et al. SARS-CoV-2 spike P681R
405 mutation enhances and accelerates viral fusion. *bioRxiv* [Internet]. 2021 Jan
406 1;2021.06.17.448820. Available from:
407 <http://biorxiv.org/content/early/2021/06/17/2021.06.17.448820.abstract>
- 408 19. Agresti A, Coull BA. Approximate Is Better than “Exact” for Interval Estimation of
409 Binomial Proportions. *Am Stat* [Internet]. 1998 Jul 14;52(2):119–26. Available from:
410 <http://www.jstor.org/stable/2685469>
- 411 20. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et
412 al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic
413 Era. *Mol Biol Evol* [Internet]. 2020 May 1;37(5):1530–4. Available from:
414 <https://doi.org/10.1093/molbev/msaa015>
- 415 21. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms
416 and methods to estimate maximum-likelihood phylogenies: assessing the performance of

417 PhyML 3.0. Syst Biol [Internet]. 2010;59(3):307–21. Available from:
418 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20525638
419

420 22. Hoang DT, Chernomor O, von Haeseler A, Minh BQ, Vinh LS. UFBoot2: Improving the
421 Ultrafast Bootstrap Approximation. Mol Biol Evol [Internet]. 2018 Feb 1;35(2):518–22.
422 Available from: <https://doi.org/10.1093/molbev/msx281>

423

424

425 **Funding**

426 Proyecto IP COVID-19 N°08, Focem COF 03/11 Covid-19.